<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584465</url>
  </required_header>
  <id_info>
    <org_study_id>GINECO-OV235</org_study_id>
    <nct_id>NCT02584465</nct_id>
  </id_info>
  <brief_title>REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression</brief_title>
  <acronym>REGOVAR</acronym>
  <official_title>A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this randomized phase II is to evaluate the benefit of regorafenib for&#xD;
      ovarian patients who reported a confirmed elevated CA-125 level under surveillance or&#xD;
      bevacizumab, compared with tamoxifen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  After surgery, most of patients with advanced ovarian/primitive peritoneal /fallopian&#xD;
           carcinoma received as first line treatment, carboplatin plus paclitaxel plus or minus&#xD;
           bevacizumab for 6 cycles followed by surveillance or bevacizumab maintenance therapy up&#xD;
           to one year (GOG (Burger et al.), ICON7 (Perren et al.), French national guidelines&#xD;
           Saint Paul de Vence (www.arcagy.org)).&#xD;
&#xD;
        -  This multi-modality approach achieves clinical responses in about 70% of patients,&#xD;
           although a majority of women eventually relapse and die from disease progression. The&#xD;
           first sign of relapse can be a progressively rising CA-125 (Tuxen et al.).&#xD;
&#xD;
        -  Biochemical-recurrent of Epithelial Ovarian Cancer (EOC) is defined as CA-125 elevation&#xD;
           above normal values without clinical evidence of disease, and can predate clinical&#xD;
           disease by approximately 3-6 months (Tuxen et al.). Even if CA-125 elevation is a&#xD;
           harbinger of EOC relapse, the question remains as to whether early therapeutic&#xD;
           intervention can translate into extending the duration of survival.&#xD;
&#xD;
        -  A few years ago, Rustin reported from ovarian cancer patients on surveillance after&#xD;
           first line treatment with isolated elevated CA-125 (without RECIST/symptoms criteria)&#xD;
           that there was no benefit to initiate a new chemotherapy compared to surveillance&#xD;
           (Rustin et al. Lancet 2010; Rustin et al. Ann Oncol 2011).&#xD;
&#xD;
        -  For patients under bevacizumab on maintenance phase at the time of the CA-125 elevation&#xD;
           without RECIST or symptoms progression, data are scare. In the GOG0218 trial, elevated&#xD;
           CA-125 did not totally complied with RECIST criteria progression. This study reported&#xD;
           that the median PFS is longer in patients with continuous bevacizumab (14.1 months),&#xD;
           compared to patients under placebo (10.3 months), using CA-125 &amp; RECIST criteria,&#xD;
           supporting the hypothesis that a maintenance treatment with an anti angiogenic agent&#xD;
           allows delaying disease progression (Burger et al. N. Engl. J. Med. 2011). In an&#xD;
           analysis of progression-free survival in which data for patients with increased CA-125&#xD;
           levels were censored, the median progression-free survival was 12.0 months in the&#xD;
           control group but 18.0 months in the bevacizumab-throughout group (hazard ratio, 0.645;&#xD;
           P&lt;0.001). The relationship of CA-125 to progressive disease (PD) may be altered in&#xD;
           bevacizumab (BV)-treated patients. In the Ocean trial elevated CA-125 was associated&#xD;
           with forthcoming progression for the majority of the patients under bevacizumab (HR&#xD;
           0.48) in the platinum sensitive population (Aghajanian et al.).&#xD;
&#xD;
        -  Current international recommendations are to continue the same strategy (surveillance or&#xD;
           maintenance bevacizumab) until RECIST or symptomatic progression regardless of the&#xD;
           CA-125 level.&#xD;
&#xD;
        -  However, some can argue that a waiting attitude is deemed unacceptable due to patient&#xD;
           anxiety over a rising CA-125 compelling a significant proportion of physicians to&#xD;
           propose a therapeutic intervention, due to the nearness of the disease progression.&#xD;
&#xD;
        -  Tamoxifen is an endocrine alternative treatment option in patients with rising CA-125.&#xD;
           Hurteau et al. studies supported the use of tamoxifen showing a 17% response rate in&#xD;
           measurable recurrent disease, 13% response rate in platinum resistant disease, observed&#xD;
           stable disease in 38% of patients lasting a median of 3 months (Hatch, et al).&#xD;
&#xD;
        -  The use of tamoxifen treatment as a control arm for isolated CA-125 is thus justified&#xD;
           based on a favorable toxicity profile compared with available cytotoxic agents and the&#xD;
           lack of interference with subsequent interventions beyond documentation of clinical&#xD;
           progression (Marckman, et al). As patients have until today no benefit to introduce a&#xD;
           new chemotherapy regimen for isolated elevated CA-125 (Rustin et al 2010), exploring new&#xD;
           anti-angiogenic agent could be clinically relevant. Agents that inhibit tumor&#xD;
           angiogenesis and invasion were considered to be ideal candidates for the experimental&#xD;
           arm given their potential to prolong the duration of disease-free survival while&#xD;
           exhibiting a more favorable toxicity profile than cytotoxic drugs.&#xD;
&#xD;
        -  Pazopanib and other multi-kinase inhibitors such as cediranib, nintenanib reported&#xD;
           activity in relapsing ovarian cancer (sensitive or resistant population) used alone in&#xD;
           several phase II trials (Matulonis et al., Ledermann et al., and Friedlander et al.).&#xD;
&#xD;
        -  Regorafenib is a new oral multi-kinase inhibitor. It inhibits kinases involved in&#xD;
           angiogenesis (VEGFR 1-3, TIE 2), signaling in the tumor microenvironment (PDGFR-Î², FGFR)&#xD;
           and oncogenesis (KIT, RET and BRAF). Inhibition of tumor growth and formation of&#xD;
           metastases were shown in vivo. Tumor activity has been reported in a variety of tumor&#xD;
           types. Regorafenib is approved in Europe for the treatment of metastatic colorectal&#xD;
           cancer in patients previously treated with, or who are not considered candidates for,&#xD;
           available therapies. An application for GIST progressing after imatinib and sunitinib&#xD;
           has obtained the AMM in Europe. The recommended dose is 160 mg taken once daily for 3&#xD;
           weeks followed by 1 week off therapy.&#xD;
&#xD;
      The objective of this randomized phase II is to evaluate the benefit of regorafenib for&#xD;
      ovarian patients who reported a confirmed elevated CA-125 level under surveillance or&#xD;
      bevacizumab, compared with tamoxifen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 28, 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free survival (PFS)</measure>
    <time_frame>4 months</time_frame>
    <description>PFS according to the RECIST 1.1 criteria, based on the investigator's assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to start of first subsequent chemotherapy (TFST)</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Second progression-Free Survival (PFS2)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS2 based on the investigator's assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>7 months</time_frame>
    <description>frequency of adverse events according to MedDRA terms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>A-Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen 40mg/day 2 film-coated tablet containing 20 mg of Tamoxifen/day until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B-Regorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib 120mg/day 3 film-coated tablet containing 40 mg of Regorafenib/day, 3 weeks/4 until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Tamoxifen: 40 mg/day</description>
    <arm_group_label>A-Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Stivarga; 120mg/day</description>
    <arm_group_label>B-Regorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
        I2 Histological confirmation of epithelial ovarian, fallopian tube, or primary peritoneal&#xD;
        cancer, I3 Rising CA-125 (according to the Rustin/GCIG criteria, see appendix 10))&#xD;
        occurring more than 6 months after the last platinum-based chemotherapy cycle (platinum&#xD;
        sensitive), I4 No symptom related to ovarian cancer progression, I6 1 or 2 prior lines of&#xD;
        platinum-based chemotherapy followed either by surveillance or bevacizumab or olaparib&#xD;
        (outside therapeutic trial) maintenance, I7 Before randomization, patients must be in CR,&#xD;
        PR or SD (RECIST version 1.1) under surveillance or maintenance with bevacizumab or&#xD;
        olaparib,&#xD;
&#xD;
        I8 Adequate bone marrow, liver and renal functions as assessed by the following laboratory&#xD;
        tests conducted within 7 days before randomization:&#xD;
&#xD;
          -  Absolute Neutrophil Count â¥ 1.5 G/L, platelets count â¥ 100 G/L, and hemoglobin â¥&#xD;
             9g/dL,&#xD;
&#xD;
          -  AST/ALT â¤ 3 x upper limit of normal (ULN) (or â¤ 5.0 x ULN if liver metastasis) and&#xD;
             total bilirubin â¤ 1.5 x ULN, Alkaline phosphatase â¤ 2.5 x ULN&#xD;
&#xD;
          -  Serum creatinine â¤ 1.5 x ULN,&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) â¥ 30 mL/min/1.73 mÂ² according to the Modification of&#xD;
             Diet Renal Disease (MDRD) abbreviated formula&#xD;
&#xD;
          -  Lipase â¤ 1.5 x ULN&#xD;
&#xD;
          -  Prothrombine time-international normalized ratio (PT-INR) &lt; 1.5 x ULN. Patients who&#xD;
             are therapeutically anticoagulated with an agent such as warfarin or heparin will be&#xD;
             allowed to participate provided that no prior evidence of underlying abnormality in&#xD;
             this parameter exists, I9 Women of childbearing potential and partners must agree to&#xD;
             use adequate contraceptive method (if no previous bilateral annexectomies) during the&#xD;
             whole study period and for up to 6 months after the last dose of study treatment; a&#xD;
             negative pregnancy test must be obtained prior to randomization,&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
        E4 Past or concurrent history of neoplasm other than ovarian cancer, except for in situ&#xD;
        carcinoma of the cervix uteri, in situ breast cancer and/or basal cell epithelioma. All&#xD;
        treats and cures cancer more than 3 years before the study entry is allowed E5 Known&#xD;
        history or symptomatic metastatic brain or meningeal tumors (head CT or MRI at screening to&#xD;
        confirm the absence of central nervous system (CNS) disease if the patient has symptoms&#xD;
        suggestive or consistent with progressive CNS disease), E6 Any prior radiotherapy to the&#xD;
        pelvis or abdomen; surgery (including open biopsy) within 4 weeks before starting study&#xD;
        drugs (24 hours for minor surgical procedures), or planned major surgery during the study&#xD;
        treatment period, E7 Any prior treatment with anti angiogenic agent such as pazopanib,&#xD;
        nintedanib or cediranib.&#xD;
&#xD;
        E8 Endocrine therapy administered within 3 years prior to randomization,&#xD;
&#xD;
        E13 History of any of the following :&#xD;
&#xD;
          -  abdominal fistula,&#xD;
&#xD;
          -  gastrointestinal perforation,&#xD;
&#xD;
          -  intra-abdominal abscess,&#xD;
&#xD;
          -  any malabsorption condition, E14 Clinically significant bleeding NCI-CTCAE version 4.3&#xD;
             Grade 3 or higher within 30 days before randomization, E15 Congestive heart failure&#xD;
             New York Heart Association (NYHA) â¥ class 2, E17 Uncontrolled hypertension (systolic&#xD;
             blood pressure (BP) &gt; 150 mmHg or diastolic pressure &gt; 90 mmHg despite optimal medical&#xD;
             management), E21 Ongoing infection &gt; Grade 2 according to NCI-CTCAE version 4.3.&#xD;
             Hepatitis B is allowed if no active replication is present. Hepatitis C is allowed if&#xD;
             no antiviral treatment is required, E23 Interstitial lung disease with ongoing signs&#xD;
             and symptoms at the time of screening,&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Olivier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>olivier.tredan@lyon.unicancer.fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte-Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84918</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Cholet</name>
      <address>
        <city>Cholet</city>
        <zip>49300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre LÃ©on BÃ©rard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de Mont-de-Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre AzurÃ©en de CancÃ©rologie</name>
      <address>
        <city>Mougins</city>
        <zip>06250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ORACLE - Centre d'Oncologie de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Catherine de Sienne</name>
      <address>
        <city>Nantes</city>
        <zip>44202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier RÃ©gional d'OrlÃ©ans</name>
      <address>
        <city>OrlÃ©ans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre CARIO - HPCA</name>
      <address>
        <city>Plerin SUR MER</city>
        <zip>22190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICO Centre RenÃ© Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de RadiothÃ©rapie - Clinique Sainte-Anne</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

